FFA
HZNP

Farther Finance Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Farther Finance Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,041
Closed -$120K – 3653
2023
Q3 		$120K Buy
1,041
+13
+1% +$1.4K 0.02% 502
2023
Q2 		$106K Sell
1,028
-1
-0.1% -$106 0.02% 444
2023
Q1 		$112K Buy
1,029
+5
+0.5% +$553 0.03% 376
2022
Q4 		$117K Buy
+1,024
New +$85.1K 0.05% 293

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farther Finance Advisors's HZNP Position: Q4 2023 in Review

Farther Finance Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 1,041 shares — an estimated $120K sold.

Farther Finance Advisors first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $120K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Farther Finance Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Farther Finance Advisors sold 1,041 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $120K.
  • Farther Finance Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Farther Finance Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $120K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Farther Finance Advisors's 13F filing for Q4 2023, filed 15 Feb 2024.